AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Factor VIIIF FactorHemophilia Avon Willebrand Factorvon Willebrand DiseasesConjugation, GeneticFactor VIIIaExtrachromosomal InheritanceFactor IXaBlood Coagulation FactorsGenetics, MicrobialBlood Coagulation Factor InhibitorsBlood Coagulation TestsEscherichia coliThrombinHeparin Cofactor IIFactor IXBlood CoagulationSexGeneticsCoenzymesMutationStreptomycinFactor VBinding SitesCollagen Type VIIITetracyclineFactor XaAdenovirus Early ProteinsIsoantibodiesRecombinant ProteinsPartial Thromboplastin TimeE2F Transcription FactorsHemarthrosisFactor XRats, Inbred F344RistocetinChromosomes, BacterialAmino Acid SequencePteridinesKineticsChloramphenicolCoagulantsDeamino Arginine VasopressinBase SequenceProtein BindingDNA, BacterialHemophilia BMolecular Sequence DataAntigensLysogenyPlasmidsFactor V DeficiencyFactor VIIColiphagesEscherichia coli ProteinsHemostasisBlood PlateletsRecombination, GeneticDrug Resistance, MicrobialImmunoelectrophoresis, Two-DimensionalPQQ CofactorE2F1 Transcription FactorDNA-Binding ProteinsF2-IsoprostanesBacterial ProteinsDrug ContaminationPhosphatidylserinesBleeding TimeProtein Structure, TertiaryMetalloproteinsElectrophoresis, Polyacrylamide GelGenesAntibodiesFibrinogenMolybdenumGenetic Complementation TestProthrombin TimeChromosome MappingThromboplastinFactor VaPlatelet AggregationTemperatureFactor VIIaMolecular Weight
Ristocetin cofactorHemophiliaFVIIIDeficiencyWillebrandActs as a cofactorPlateletAntigenInhibitorsVIIIaProteinHemostasisProteinsFibrinogenPhospholipidAssayDeficienciesThrombinExtracellularPlasma factor VIII levelsAntihemophilicRecombinant factorSupplAntibodyFunctionalLevels2021DesmopressinPeptidesBleedingActivityEnzymesXasePatientsBiochemicalReconstitutionREACTIONSThrombosisTissue factor paSerine proteasesComplexesClotExtrinsicDDAVPFindingsFunctionLocated on the X chromosomeVariantsTranscription factorsCalcium
Ristocetin cofactor6
Hemophilia18
  • HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. (nih.gov)
  • Hemophilia A is a congenital disorder caused by deficiency or malfunction of coagulation factor (F) VIII. (nih.gov)
  • In type 2 N, there is impaired binding of VWF to factor VIII and significant reduction in factor VIII levels (ie, to 1 to 5%) similar to that seen in hemophilia A. (msdmanuals.com)
  • Hemophilia Hemophilias are common hereditary bleeding disorders caused by deficiencies of either clotting factor VIII or IX. (msdmanuals.com)
  • As a result, patients with mutations in either factor VIII or IX, are born with a bleeding disorder called hemophilia. (hstalks.com)
  • In the case of factor VIII deficiency, which is the more common form of the two diseases, the disease is called hemophilia A. Because both genes are X-linked, it is boys that are born with the disease, whereas females are carriers. (hstalks.com)
  • Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. (nih.gov)
  • The deficiency of factor VIII activity in humans is associated with a congenital bleeding disorder, called hemophilia A, which affects about 1 in 5000 males. (diapharma.com)
  • Hemophilia A patients are treated with factor VIII concentrate for maintenance of normal hemostasis but regrettably prophylactic treatment is not in general use worldwide. (diapharma.com)
  • Hence, factor VIII levels are of importance to measure not only for diagnosing and monitoring hemophilia A but also for thrombophilia investigations. (diapharma.com)
  • Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. (medscape.com)
  • Antihemophilic Factor/von Willebrand Factor Complex (Human), HUMATE-P ® is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). (humate-p.com)
  • In Hemophilia A (factor VIII deficiency) and B (factor IX deficiency) - bleeding time is normal, APTT is prolonged Glanzmann thrombasthenia is a genetic platelet disorder in which the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) complex is either deficient or present but dysfunctional. (medicospace.com)
  • Deficiency of FVIII activity leads to hemophilia A. Recombinant FVIII Fc fusion protein (rFVIIIFc) was developed to extend factor half-life, thus decreasing treatment burden and increasing protection in patients. (isth.org)
  • Hemophilia is a hemorrhagic disease caused by a congenital deficiency or dysfunction of coagulation factor VIII (FVIII) or coagulation factor IX (FIX). (justia.com)
  • The former is called hemophilia A and the latter is called hemophilia B. Genes for both factors are located on the X chromosome, and since genetic defects take the X-chromosome-linked recessive hereditary form, 99% or more of the patients who develop the disease are men. (justia.com)
  • These proteins are indispensable for proper functioning of the coagulation cascade as a functional absence of factor VIII and factor IX is associated with the bleeding disorders hemophilia A and hemophilia B. Factor VIII is composed of a series of repeated domains which appear in the order A1-a1-A2-a2-B-a3-A3-C1-C2. (sanquin.org)
  • As a consequence, hemophilia patients require frequent intravenous infusions during coagulation factor substitution therapy. (sanquin.org)
FVIII11
  • Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). (wikipedia.org)
  • No longer protected by vWF, activated FVIII is proteolytically inactivated in the process (most prominently by activated protein C and factor IXa) and quickly cleared from the blood stream. (wikipedia.org)
  • Laboratory Coagulation Test Interference: HEMLIBRA interferes with activated clotting time (ACT), activated partial thromboplastin time (aPTT), and coagulation laboratory tests based on aPTT, including one-stage aPTT-based single-factor assays, aPTT-based Activated Protein C Resistance (APC-R), and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. (nih.gov)
  • Procoagulant factor VIII (FVIII) is an essential cofactor in the coagulation cascade. (isth.org)
  • The involvement of Fc or FVIII domains in mediating rFVIIIFc interaction with monocytes was probed using antibodies blocking each type of FcγRs, or anti-FVIII antibodies and von Willebrand factor (VWF) binding to various FVIII domains. (isth.org)
  • For patients experiencing bleeding, hemostasis cannot be ensured until factor VIII coagulation activity (FVIII:C) has reached 40 IU/deciliter (dL) (i.e., 40% of normal activity). (drugs.com)
  • If the patient's baseline plasma FVIII:C level is below 40%, or is unknown, administer an approved recombinant (non-von Willebrand factor containing) factor VIII (rFVIII) with the first infusion of VONVENDI in order to achieve a hemostatic plasma level of FVIII:C. However, if an immediate rise in FVIII:C is not necessary or if the baseline FVIII:C level is sufficient to ensure hemostasis, administer VONVENDI without rFVIII. (drugs.com)
  • The initial dose of VONVENDI should achieve greater than 60% of von Willebrand factor (VWF) levels (based on VWF:RCo greater than 60 IU/dL) and an infusion of rFVIII should achieve factor VIII levels greater than 40% (FVIII:C greater than 40 IU/dL). (drugs.com)
  • In a major bleeding episode when baseline factor VIII level is unknown, rFVIII should be administered to achieve a target peak level of FVIII:C 80 to100 IU/dL, based on the approximate mean recovery of 2 (IU/dL)/(IU/kg). (drugs.com)
  • The half-life of FVIII formulations in blood is approximately 8 to 19 hours. (justia.com)
  • Their mechanisms of action are not dependent on FVIII function, that is, on the function of catalyzing the activation of blood coagulation factor X (FX) by activated blood coagulation factor IX (FIXa). (justia.com)
Deficiency10
  • Copper is a required cofactor for factor VIII and copper deficiency is known to increase the activity of factor VIII. (wikipedia.org)
  • Von Willebrand disease is caused by a deficiency or poor functioning of von Willebrand factor. (medlineplus.gov)
  • Deficiency of factor VIII activity results in a marked reduction of factor IXa a. (rochester.edu)
  • Deficiency of factor VIII activity results in a marked reduction of factor IXa activity and in the subsequent rates of factor Xa generated during the propagation phase of coagulation. (rochester.edu)
  • Von Willebrand disease (VWD) is a hereditary quantitative deficiency or functional abnormality of von Willebrand factor (VWF), which causes platelet dysfunction. (msdmanuals.com)
  • The extent of factor deficiency determines the probability and severity of bleeding. (msdmanuals.com)
  • This may be explained by the fact that although there is often no abnormal bleeding tendency in heterzygotes with factor V deficiency, prolonged PT and APTT times are observed (ref: Sartori et al. (diapharma.com)
  • Protein S is a vitamin K dependent co-factor of protein C. Deficiency of Protein S results in a hypercoagulable state, which is treated with anticoagulation. (ispub.com)
  • Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies. (rxreasoner.com)
  • Follow-up for organic factors that affect the patients clinical condition leading to pulmonary artery pressures are acceptable only in the kidney to increase reflex excitability in neurons descending from the beginning of this fluid or relative deficiency of na+ and water lost. (albionfoundation.org)
Willebrand23
Acts as a cofactor2
Platelet4
  • Every monomer contains particular binding domains that provide them the capacity to interact and bind other proteins specifically, factor VIII, collagen, and some platelet receptors. (medscape.com)
  • The alpha granules contain hemostatic proteins such as fibrinogen, vWf, and growth factors (eg, platelet-derived growth factor and transforming growth factors). (medscape.com)
  • Platelet disorders lead to defects in primary hemostasis and produce signs and symptoms different from coagulation factor deficiencies (disorders of secondary hemostasis). (medscape.com)
  • Primary hemostasis involves the formation of a platelet plug at the site of injury, and secondary hemostasis involves coagulation , where several clotting factors come into play to form a fibrin mesh over the platelet plug to reinforce it, and form the blood clot. (osmosis.org)
Antigen5
  • vWF antigen, vWF activity, and factor VIII activity are required before performing this test. (medscape.com)
  • Factor VIII related antigen is used as a target for immunohistochemistry, where endothelial cells, megakaryocytes, platelets and mast cells normally stain positive. (wikipedia.org)
  • Bleeding time and Factor VIII coagulant activity, Factor VIII antigen and von Willebrand's Factor activities should be checked during administration of desmopressin to ensure that adequate levels are being achieved. (rxmed.com)
  • Desmopressin is not indicated for the treatment of severe classic Type I von Willebrand's disease and Type IIb and when there is evidence of an abnormal molecular form of Factor VIII antigen (see Contraindications). (rxmed.com)
  • The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively. (justia.com)
Inhibitors4
  • the incidence of these inhibitors is dependent of various factors, including the factor VIII product itself. (wikipedia.org)
  • When mechanical or chemical damage of the vascular wall occurs, subendothelial TF is expressed/exposed to blood flow and binds plasma factor VIIa, which circulates as an enzyme at a concentration of approximately 0.1 nM (1% of plasma factor VII) [ 4 ] and escapes the inhibition by serine proteases inhibitors because of its poor enzymatic qualities [ 1 , 5 ]. (hindawi.com)
  • TF-triggered procoagulant response is also down-regulated by the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI) and antithrombin (AT). (hindawi.com)
  • Testing for inhibitors is indicated when bleeding is not controlled after infusion of adequate amounts of factor concentrate during a bleeding episode. (medscape.com)
VIIIa10
Protein15
  • Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. (wikipedia.org)
  • Factor VIII protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to the A domains of the copper-binding protein ceruloplasmin. (wikipedia.org)
  • Tissue factor (TF) is an integral membrane protein that is essential to life. (hindawi.com)
  • TF is an integral transmembrane protein expressed by various cells, is a component of the factor VIIa-TF complex enzyme and is essential for normal hemostasis [ 1 , 2 ]. (hindawi.com)
  • In addition to its multiple procoagulant roles, thrombin also acts as an anticoagulant when combined with the cofactor thrombomodulin in the protein Case complex. (hindawi.com)
  • Factor VIII is a non-enzymatic plasma protein that is essential for normal blood coagulation. (diapharma.com)
  • clotting factor VIII (8), another important protein that helps your blood clot. (nih.gov)
  • 1 It functions to express the activated form of protein C, which inhibits the blood clotting cascade at the levels of Factor V and Factor VIII. (ispub.com)
  • Protein S is a vitamin K dependent co-factor of protein C. Protein C acts by neutralizing activated factors V and VIII, and by exhibiting an inhibitory action of plasminogen activator. (ispub.com)
  • Duan S, Kis-Toth K, Rajani G, Peters R, Salas J. The Fc and C1/C2 Domains of Recombinant Factor VIII Fc Fusion Protein Engage Monocytes in an FcgammaRII-Dependent Manner to Reduce Their Differentiation Potential into Osteoclasts [abstract]. (isth.org)
  • This gene encodes a protein which is a member of the Sp/KLF family of transcription factors. (nih.gov)
  • Coagulation was enhanced at lower lipid/factor ratios, consistent with a more concentrated area for protein binding. (nih.gov)
  • The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. (cusabio.com)
  • Previously, we have identified LDL receptor-related protein (LRP) as one cellular receptor that contributes to factor VIII clearance. (sanquin.org)
  • When protein S joins this complex, it activates the proteolytic site of protein C, which cleaves and inactivates active factor V, a cofactor for factor X in the common pathway, and factor VIII, a cofactor for factor IX in the intrinsic pathway. (osmosis.org)
Hemostasis4
  • This negative surface provides binding sites for enzymes and cofactors of the coagulation system, resulting in the formation of a clot (secondary hemostasis). (medscape.com)
  • Overview of Hemostasis Hemostasis, the arrest of bleeding from an injured blood vessel, requires the combined activity of Vascular factors Platelets Plasma coagulation factors Regulatory mechanisms counterbalance. (msdmanuals.com)
  • von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. (nih.gov)
  • It is a component of the factor VIIa-TF complex enzyme and plays a primary role in both normal hemostasis and thrombosis. (hindawi.com)
Proteins4
  • The formation of this blood clot that seals an injured vessel requires a cascade of enzymatic reaction that happen in the blood, and the proteins that carry out these reactions are referred to as coagulation factors. (hstalks.com)
  • In contrast to other α-granule proteins, fibrinogen and factor V are exceptional as they are derived completely from endocytosis from plasma. (sanquin.org)
  • Proteins called clotting factors are needed for blood to clot properly and help prevent too much bleeding. (kidshealth.org)
  • Myc genes encode proteins that are transcription factors that control hESC behavior through regulating levels of other factors. (ca.gov)
Fibrinogen3
  • Thrombin cleaves fibrinogen into fibrin which polymerizes and crosslinks (using factor XIII) into a blood clot. (wikipedia.org)
  • Thrombin accelerates its own generation via several feed-back reactions, cleaves fibrinogen, and activates factor XIII, which leads to the formation of a crosslinked insoluble fibrin clot [ 6 , 7 ] (Figure 1 ). (hindawi.com)
  • It further seems remarkable that megakaryocytes comprise specialized mechanisms for the endocytosis and subsequent storage of factor V and fibrinogen only. (sanquin.org)
Phospholipid1
  • The coagulation cascade comprises several serine proteases that act in combination with a non-enzymatic co-factor on phospholipid-containing membranes. (sanquin.org)
Assay1
  • Chromogenix Coatest® SP4 Factor VIII is a chromogenic assay kit for the in vitro diagnostic photometric determination of factor VIII activity in citrated plasma. (diapharma.com)
Deficiencies1
  • To detect factor deficiencies and related coagulopathies such as found in disseminated intravascular coagulation (DIC). (unboundmedicine.com)
Thrombin4
Extracellular1
  • 8. Extracellular pH affects the fluorescence lifetimes of metabolic co-factors. (nih.gov)
Plasma factor VIII levels1
Antihemophilic1
  • The drug Alphanate (antihemophilic factor) is approved to decrease bleeding in people with the disease who must have surgery or any other invasive procedure. (medlineplus.gov)
Recombinant factor2
  • During later years recombinant factor VIII has been approved for therapeutic use, which minimizes the risk of viral transmission. (diapharma.com)
  • If recombinant factor VIII is administered, see recombinant factor VIII package insert for reconstitution and administration instructions. (drugs.com)
Suppl1
Antibody1
  • We have been long engaged in creating and clinically developing a humanized anti-FIXa/FX asymmetric bispecific IgG antibody with a FVIIIa-cofactor activity. (nih.gov)
Functional1
  • Since 1999 he has been working as a Research Assistant Professor in the Department of Biochemistry and Biophysics at University of Rochester studying on the structural and functional analyses of blood coagulation factor VIII. (rochester.edu)
Levels7
  • People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism. (wikipedia.org)
  • How do factor V and VIII levels affect the Chromogenix Coatest® APC Resistance tests? (diapharma.com)
  • Her factor VIII levels are 10% of normal. (medicospace.com)
  • When repeated infusions are required, monitor factor VIII levels to determine if rFVIII is required with subsequent infusions. (drugs.com)
  • A preoperative dose of VONVENDI may be administered 12 to 24 hours prior to surgery to allow the endogenous factor VIII levels to increase to at least 30 IU/dL (minor surgery) or 60 IU/dL (major surgery) before the loading dose (1 hour preoperative dose) of rVWF, with or without rFVIII, is administered. (drugs.com)
  • Salmonella typhimurium strains TAl535, TA1537, TA98 and TAl00 and Escherichia coli strain WP2uvrA were treated with the test item using the Ames plate incorporation method at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). (europa.eu)
  • Eight test item dose levels were selected in the main test in order to achieve both four non-toxic dose levels and the potential toxic limit of the test item following the results from the first mutation test. (europa.eu)
20211
Desmopressin1
  • Either directly or indirectly, desmopressin causes these factors to be released very rapidly from their endothelial cell storage sites. (rxmed.com)
Peptides1
  • Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides. (chop.edu)
Bleeding3
  • A family history of a bleeding disorder is the primary risk factor. (medlineplus.gov)
  • Blood plasma or certain factor VIII preparations may also be used to decrease bleeding. (medlineplus.gov)
  • In summary, innate immune-derived eoxPL enhance calcium-dependent coagulation factor function, and their potential utility in bleeding disorders is proposed. (nih.gov)
Activity9
  • Alternatively, Cu2+ enhanced the inter-subunit affinity ~100-fold but yielded a dimer lacking cofactor activity. (rochester.edu)
  • Site-directed mutagenesis is employed to identify residues important in Ca2+ binding to factor VIII and resultant effects of this binding on activity. (rochester.edu)
  • Several acidic amino acids within segment 110-126 of the A1 domain of factor VIII that likely participate in the coordination of Ca2+ necessary for generation of maximal cofactor specific activity. (rochester.edu)
  • TFPI serves to attenuate the activity of the extrinsic factor Xase, the trigger of coagulation. (hindawi.com)
  • The generated factor Xa and thus the intensity of color is proportional to the factor VIII activity in the sample. (diapharma.com)
  • There is now also growing evidence that elevated factor VIII activity is a risk factor for thrombosis. (diapharma.com)
  • Labcorp test details for Factor II Activity. (auxiliarfisioterapia.es)
  • After activation, the A2 domain rapidly dissociates from activated factor VIII resulting in a dampening of the activity of the activated factor X-generating complex. (sanquin.org)
  • In this line of research, we employ chemical footprinting mass spectrometry (MS) as well as hydrogen-deuterium exchange MS to assess the molecular mechanism behind cofactor function and the enzymatic activity of serine proteases. (sanquin.org)
Enzymes1
  • Magnesium aids digestion by acting as a co-factor for enzymes involved in the digestion process, helping break down food and absorb nutrients. (xendurance.com)
Xase3
  • A Glu113Ala Mutation within a Factor VIII Ca(2+)-Binding Site Enhances Cofactor Interactions in Factor Xase. (rochester.edu)
  • Upon an injury to the vessel wall, TF, a membrane-bound cofactor, is exposed to circulating factor VIIa, forming the extrinsic factor Xase, a complex enzyme. (hindawi.com)
  • Factor IX and factor X are converted to the serine proteases factor IXa and factor Xa, which are the enzymatic components of the intrinsic factor Xase and the prothrombinase complexes, respectively. (hindawi.com)
Patients2
  • Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. (humate-p.com)
  • Caution should be exercised and antithrombotic measures considered, particularly in patients with risk factors for thrombosis. (humate-p.com)
Biochemical2
  • Pharmacokinetic factors influencing risk assessment: saturation of biochemical processes and cofactor depletion. (nih.gov)
  • It is the purpose of this monograph to present an overview of biochemical and clinical data on factor VIII and to provide comprehensive information on methodological aspects and on the use of the Coamatic® and Coatest® Factor VIII kits. (diapharma.com)
Reconstitution2
  • Reconstitute with 12.0 mL of sterile water or NCCLS type II water, to obtain a concentration of 2.7 mmol/L. Stability after reconstitution: 3 months at 2-8°C. (diapharma.com)
  • Stability after reconstitution: 12 hours at 2-8°C. The solution can be stored frozen in aliquots at -20°C (or at lower temperature) for 3 months. (diapharma.com)
REACTIONS3
  • For example, factor IX is an enzyme that is part of this cascade that is critical to carry out one of these reactions, and it has a cofactor called factor VIII, which is required for factor IX to function properly. (hstalks.com)
  • With a vascular injury, TF becomes exposed to blood and binds plasma factor VIIa, and the resulting complex initiates a series of enzymatic reactions leading to clot formation and vascular sealing. (hindawi.com)
  • Collectively taken, miRNAs can be viewed as a new regulatory layer of inflammatory reactions operating as intracellular effectors of well-known pro- and anti-inflammatory mediators, including PAMPs and DAMPs, inflammatory, and anti-inflammatory cytokines and macrophage polarizing factors (e.g. (frontiersin.org)
Thrombosis1
  • Under physiological circumstances, the resistance of the endothelial cell lining to interactions with platelets and coagulation factors prevents thrombosis. (medscape.com)
Tissue factor pa1
  • Dr. Camire's lab uncovered surprising observations that have fundamentally shifted current thinking about FV activation and its regulation by tissue factor pathway inhibitor. (chop.edu)
Serine proteases1
Complexes1
  • To explore molecular mechanisms, the ability of eoxPL to stimulate individual isolated coagulation factor/cofactor complexes was tested in vitro. (nih.gov)
Clot2
  • It turns out that if one of these coagulation factors is defective, the blood loses the ability to clot. (hstalks.com)
  • and activates factor XIII to form a cross-linked fibrin clot. (hindawi.com)
Extrinsic1
  • Extrinsic tenase (FVIIa/tissue factor [TF]), intrinsic tenase (FVIIIa/FIXa), and prothrombinase (FVa/FXa) all were enhanced by both HETE-PEs and HETE-PCs, suggesting a common mechanism involving the fatty acid moiety. (nih.gov)
DDAVP1
  • Treatment may include DDAVP (desamino-8-arginine vasopressin). (medlineplus.gov)
Findings1
  • Our findings revealed that the lysine couple K1967-K1968 within region T1964-Y1971 has an opposite contribution to activated factor VIII stability. (sanquin.org)
Function2
  • My research focuses on the role of metal ions for structural integrity and function of factor VIII. (rochester.edu)
  • In its job as a transcription factor, Myc binds to DNA in stem cells and regulates the structure and function of the DNA through a process called epigenetics. (ca.gov)
Located on the X chromosome1
Variants2
  • Cell surface binding proved to be less effective for the fluorescent factor VIII-YFP variants K2092A, F2093A and K2092A/F2093A. (sanquin.org)
  • Finally, flow cytometry analysis revealed a major reduction of endocytic uptake of these factor VIII-YFP variants. (sanquin.org)
Transcription factors1
  • My current projects aim to elucidate the role of transcription factors in different types of oncogenesis and molecular mechanisms of melanoma metastasis. (kolabtree.com)
Calcium2